Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 7;12(11):e0187667.
doi: 10.1371/journal.pone.0187667. eCollection 2017.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Abir Salwa Ali  1 , Malin Grönberg  1 , Birgitte Federspiel  2 , Jean-Yves Scoazec  3 , Geir Olav Hjortland  4 , Henning Grønbæk  5 , Morten Ladekarl  6 , Seppo W Langer  7 , Staffan Welin  1 , Lene Weber Vestermark  8 , Johanna Arola  9 , Pia Österlund  10   11 , Ulrich Knigge  12 , Halfdan Sorbye  13 , Lars Grimelius  14 , Eva Tiensuu Janson  1
Affiliations

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Abir Salwa Ali et al. PLoS One. .

Abstract

Background: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC.

Materials and methods: Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS).

Results: All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses.

Conclusion: In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Representative images of immunostainings.
(A, B) Immunoreactivity for chromogranin A, (C, D) Ki67 and (E, F) p53. The left panel demonstrates staining of a pancreatic primary tumor. The right panel shows the respective staining from a rectal primary tumor. Scale bar = 100 μm.
Fig 2
Fig 2. Immunohistochemical images of scattered and dense staining pattern.
Scattered and dense staining pattern for two p53 immunoreactive tumors. (A) Scattered type. Single immunoreactive cells spread out in the whole tumor sample. (B) Dense type. Widespread immunoreactivity of the entire tumor specimen. (C) and (D) represent Ki67 for each tumor respectively. Scale bar = 100 μm.
Fig 3
Fig 3. Kaplan-Meier curves.
Kaplan-Meier survival curves for GEP-NECs divided according to primary tumor origin and p53 immunoreactivity. (A) Progression-free survival (PFS) for the complete cohort of 124 patients, p = 0.97. (B) Overall survival (OS) for the complete cohort of 124 patients, p = 0.54. (C) PFS for colorectal patients p = 0.03 (D) and (E) PFS and OS for colorectal patients with distant metastases, p = 0.01 and p = 0.02 respectively.
See this image and copyright information in PMC

References

    1. Bosman FT. World Health Organization., and International Agency for Research on Cancer., WHO classification of tumours of the digestive system 4th ed. World Health Organization classification of tumours. France: Lyon: IARC Press, 2010.; 2010.
    1. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60. Epub 2012/09/13. doi: 10.1093/annonc/mds276 . - DOI - PubMed
    1. Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192–202. Epub 2016/06/04. doi: 10.1097/PAS.0000000000000662 ; PubMed Central PMCID: PMC4988129. - DOI - PMC - PubMed
    1. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology. 2017;104(1):85–93. Epub 2016/11/03. doi: 10.1159/000445165 . - DOI - PubMed
    1. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23. Epub 2014/04/29. doi: 10.1002/cncr.28721 . - DOI - PubMed

MeSH terms